Insider Buying: ProQR Therapeutics (NASDAQ:PRQR) Director Purchases $231,000.00 in Stock

ProQR Therapeutics N.V. (NASDAQ:PRQR) Director Bart Filius purchased 150,000 shares of the business’s stock in a transaction on Friday, June 26th. The shares were acquired at an average price of $1.54 per share, with a total value of $231,000.00. Following the purchase, the director owned 150,000 shares of the company’s stock, valued at approximately $231,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

ProQR Therapeutics Trading Up 3.4%

PRQR stock opened at $1.81 on Friday. ProQR Therapeutics N.V. has a 1-year low of $1.33 and a 1-year high of $3.10. The firm has a market cap of $190.70 million, a P/E ratio of -3.62 and a beta of 0.04. The business’s 50 day moving average is $1.60 and its 200-day moving average is $1.70.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the consensus estimate of ($0.15). The business had revenue of $2.35 million during the quarter, compared to the consensus estimate of $5.19 million. ProQR Therapeutics had a negative return on equity of 84.87% and a negative net margin of 331.33%. Sell-side analysts forecast that ProQR Therapeutics N.V. will post -0.52 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Osaic Holdings Inc. grew its holdings in ProQR Therapeutics by 59.6% during the 2nd quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares during the last quarter. Guggenheim Capital LLC bought a new position in shares of ProQR Therapeutics in the fourth quarter worth about $35,000. Moody Lynn & Lieberson LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $50,000. Invesco Ltd. acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth approximately $51,000. Finally, Axiom Investment Management LLC bought a new stake in shares of ProQR Therapeutics during the first quarter valued at approximately $53,000. 32.65% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PRQR. Chardan Capital lowered their target price on shares of ProQR Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a report on Friday, June 26th. Citigroup restated a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. JonesTrading decreased their price objective on shares of ProQR Therapeutics from $11.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, June 26th. Oppenheimer began coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They set an “outperform” rating and a $9.00 price objective for the company. Finally, Weiss Ratings cut shares of ProQR Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, ProQR Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $7.33.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.